Project Details
Description
An Open-label treatment otion of Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma.
| Status | Finished |
|---|---|
| Effective start/end date | 3/15/11 → 3/15/13 |
Funding
- SEAGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.